Navigation Links
Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014
Date:7/25/2014

NEWARK, Calif., July 25, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will release second quarter fiscal year 2014 financial results after the market closes on Wednesday, August 6, 2014. The Company will host a conference call beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its results.

Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

About Depomed

Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.  Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults.  Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform®<
'/>"/>

SOURCE Depomed, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
2. Depomed To Present At Jefferies 2012 Global Health Care Conference
3. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
4. Depomed To Present At JMP Securities 7th Annual Healthcare Conference
5. Depomed To Report Second Quarter Fiscal Year 2012 Financial Results On Thursday, August 2, 2012
6. Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference
7. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
8. Depomed To Present At UBS Global Life Sciences Conference
9. Depomed To Report Third Quarter Fiscal Year 2012 Financial Results On Monday, November 5, 2012
10. Depomed Reports Third Quarter Financial Results
11. Depomed To Present At Lazard 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... July 7, 2015   Decision Resources Group ... in dialysis patient management in the U.S. versus ... by U.S. and EU5 nephrologists from approximately 1,870 ... are the most commonly used renal medications in ... differs considerably between the two regions.      ...
(Date:7/7/2015)... FRANCISCO , July 7, 2015 ... reach USD 1,197.7 million by 2020, growing at an estimated ... new study by Grand View Research, Inc. Introduction of innovative ... coupled with growing awareness levels pertaining to the advantages of ... the next six years. In addition, presence of untapped growth ...
(Date:7/7/2015)... , July 7, 2015 EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering of 32,000,000 units. Each unit ... Series A warrant to purchase one share of common ... Investors whose purchase of units in the offering would ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... CHICAGO and ORANGE, Calif., Feb. 23, 2011 ... (SJHS), a $4.6 billion not-for-profit Catholic healthcare system based in ... in California, West Texas and Eastern New Mexico, has selected ... MDRX ) to streamline patient movement through their ...
... Caliper Life Sciences, Inc. (Nasdaq: ... announced a co-marketing agreement which will leverage Covaris, ... microfluidics technologies to develop automated workflows for next ... suite of solutions for library construction, sample analysis, ...
Cached Medicine Technology:St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 2St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 3St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 4St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 5Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 2Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 3
(Date:7/7/2015)... ... July 07, 2015 , ... This week Northeast Nebraska ... new website. The website’s goal is to provide patients with detailed information about ... including requesting appointments online. , Part of the center’s rebranding efforts, the website ...
(Date:7/7/2015)... Washington (PRWEB) , ... July ... ... San Francisco-based Hope Consulting announced today that the two firms have merged ... in the social, health and biopharma sectors. The merger combines SwitchPoint’s strategy ...
(Date:7/7/2015)... ... , ... Greatist today announced the acquisition of Blood, Sweat ... most fun activities to do with friends. , The acquisition of BSC strengthens Greatist’s ... for events, e-commerce, and brand partnerships. , “I’ve been a huge fan of Blood, ...
(Date:7/7/2015)... ... 07, 2015 , ... Quadrino Law Group is pleased to announce the relocation ... 11747. The new facility is a state of the art building, located with ... the firm's CEO and founder, said, "We are pleased to service our clients from ...
(Date:7/7/2015)... ... ... SC&H Group, a leading audit, tax, and consulting firm, recently hosted its ... company-wide volunteering efforts. , On an annual basis, in coordination with Business Volunteers ... throughout Baltimore and Washington D.C. , This year, SC&H Group’s team in ...
Breaking Medicine News(10 mins):Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:SC&H Group Celebrates 9th Annual Day of Service 2
... juice daily could slow the progress of prostate cancer, minimise ... a new study. ,Researchers led by Allan Pantuck ... who had undergone surgery or radiation treatment for prostate cancer ... returning, reported the online edition of BBC News. , ...
... Tamil Nadu government has directed the state prisons department to ... accused in the 1998// serial blasts Abdul Nasser Mahdhani in ... prison after his arrest in March 1998, 45 days after ... be suffering from blood pressure, diabetes, spinal proble and weight ...
... compared with sonography and CT proves to be a ... ,Massimo Valentino, MD, lead author of the study ... compare the diagnostic value of sonography, contrast-enhanced sonography, and ... blunt abdominal trauma patients”. ,The study was ...
... lack of recreational facilities, stores, churches and schools within ... study is thought to be the first to examine ... rural communities. It builds upon previous Saint Louis University ... features of a community that encourage physical activity, which ...
... Rochester Medical Centre say that the antipsychotic drug, clozapine ... most effective anti-psychotic drug available. ,"Clozapine is ... long-term health implications. This study suggests that patients who ... and a hard place," said J. Steven Lamberti, the ...
... ENT pioneers have found a new method to reform the ... ,Senior investigator of the study, Eric Moore, M.D., said ... and facial abnormalities would be seen in mandible-removed oral cancer ... a huge advantage for patients and a good tool for ...
Cached Medicine News:Health News:New Tool Found to be Effective in Assessing Blunt Abdominal Trauma 2Health News:Environmental Factors Leads to Obesity in Rural Communities 2Health News:Jaw Reconstruction could be Possible in Oral Cancer Patients 2Health News:Jaw Reconstruction could be Possible in Oral Cancer Patients 3
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
Medicine Products: